263 related articles for article (PubMed ID: 17706177)
1. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential.
Mercer JR
J Pharm Pharm Sci; 2007; 10(2):180-202. PubMed ID: 17706177
[TBL] [Abstract][Full Text] [Related]
2. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
3. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
4. [Present status of PET images: clinical FDG PET in oncology].
Inoue T
Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Nov; 59(13):737-44. PubMed ID: 10614103
[TBL] [Abstract][Full Text] [Related]
5. Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients.
Tagliabue L; Del Sole A
Eur J Intern Med; 2014 Jan; 25(1):6-11. PubMed ID: 23910561
[TBL] [Abstract][Full Text] [Related]
6. Two decades at the cross-roads of biology, physics and epidemiology: lessons learned in [18F-]FDG positron emission tomography in oncology.
Rizvi SN; Comans EF; Boellaard R; van Tinteren H; Hoekstra OS
Eur J Cancer; 2010 Aug; 46(12):2150-8. PubMed ID: 20561780
[TBL] [Abstract][Full Text] [Related]
7. 18-Fluorodeoxyglucose imaging in oncology.
Harolds JA
J Okla State Med Assoc; 1999 Sep; 92(9):457-61. PubMed ID: 10504797
[TBL] [Abstract][Full Text] [Related]
8. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
Kumar R; Dhanpathi H; Basu S; Rubello D; Fanti S; Alavi A
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):50-65. PubMed ID: 18235421
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography: clinical applications in oncology. Part 1.
Kumar R; Nadig MR; Chauhan A
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1079-94. PubMed ID: 16336099
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
Shokeen M; Anderson CJ
Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
12. Non-[18F]FDG PET in clinical oncology.
Groves AM; Win T; Haim SB; Ell PJ
Lancet Oncol; 2007 Sep; 8(9):822-30. PubMed ID: 17765191
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.
Coenen HH; Elsinga PH; Iwata R; Kilbourn MR; Pillai MR; Rajan MG; Wagner HN; Zaknun JJ
Nucl Med Biol; 2010 Oct; 37(7):727-40. PubMed ID: 20870148
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.
Mankoff DA; Eary JF; Link JM; Muzi M; Rajendran JG; Spence AM; Krohn KA
Clin Cancer Res; 2007 Jun; 13(12):3460-9. PubMed ID: 17575208
[TBL] [Abstract][Full Text] [Related]
15. Clinical role of FDG PET in evaluation of cancer patients.
Kostakoglu L; Agress H; Goldsmith SJ
Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
[TBL] [Abstract][Full Text] [Related]
16. [Imaging of cancer using positron emission tomography].
Goldman S; Vanderhoeft A; Lebeau de Hemricourt E; Dusart M; Damhaut P; Wikler D
Rev Med Brux; 1999 Sep; 20(4):A365-8. PubMed ID: 10523925
[TBL] [Abstract][Full Text] [Related]
17. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
Shiue CY; Welch MJ
Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
[TBL] [Abstract][Full Text] [Related]
18. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies.
Fukuchi K; Ohta H; Matsumura K; Ishida Y
Br J Radiol; 2007 Jan; 80(949):3-11. PubMed ID: 17005513
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
20. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond.
Mankoff DA; Bellon JR
Semin Radiat Oncol; 2001 Jan; 11(1):16-27. PubMed ID: 11146039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
